Poziotinib is an EGFR/HER2 inhibitor that showed, in the ZENITH20 trial, a 28–39% objective response rate, a 70–73% disease control rate, and a 74–80% tumor reduction rate in pretreated and treatment-naïve NSCLC patients with HER2 20 exon mutations [147,148]. Here, ERBB2 is linked to non-small cell lung carcinoma.